Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gain Therapeutics, Inc. - Common Stock (NQ:GANX)

1.660 -0.060 (-3.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 508,818
Open 1.730
Bid (Size) 1.670 (2)
Ask (Size) 1.740 (8)
Prev. Close 1.720
Today's Range 1.650 - 1.749
52wk Range 1.360 - 3.190
Shares Outstanding 27,132,588
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-28.4%
-28.4%
1 Month
+7.1%
+7.1%
3 Month
-4.0%
-4.0%
6 Month
-21.3%
-21.3%
1 Year
+12.9%
+12.9%

More News

Read More
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
US Futures Trade Mixed As June Inflation Ticks Up: ASML, Morgan Stanley, Goldman Sachs, BofA Earnings In Focus
Via Benzinga
Topics Economy
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Tuesday's after hours session: top gainers and losers
Via Chartmill
Gain Therapeutics Announces Proposed Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate in Upcoming Investor Conferences
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate at The Citizens Life Sciences Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
Via Get News
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease
Via ACCESS Newswire
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Gain Therapeutics, Inc. - Common Stock publicly traded?
Yes, Gain Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Gain Therapeutics, Inc. - Common Stock trade on?
Gain Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Gain Therapeutics, Inc. - Common Stock?
The ticker symbol for Gain Therapeutics, Inc. - Common Stock is GANX on the Nasdaq Stock Market
What is the current price of Gain Therapeutics, Inc. - Common Stock?
The current price of Gain Therapeutics, Inc. - Common Stock is 1.660
When was Gain Therapeutics, Inc. - Common Stock last traded?
The last trade of Gain Therapeutics, Inc. - Common Stock was at 09/12/25 04:00 PM ET
What is the market capitalization of Gain Therapeutics, Inc. - Common Stock?
The market capitalization of Gain Therapeutics, Inc. - Common Stock is 45.04M
How many shares of Gain Therapeutics, Inc. - Common Stock are outstanding?
Gain Therapeutics, Inc. - Common Stock has 45M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.